AXIM Biotechnologies, an healthcare solutions company focused on oncological research, has announced the development of NeuCovix, a rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells, according to a press release from the company.
Unlike currently available serological COVID-19 tests that detect an antibody response to the virus, AXIM’s rapid 10-minute test measures a specific subpopulation of antibodies to block binding of the virus to host cell receptors. While there are expensive, time-consuming laboratory tests that measure neutralizing antibodies, NeuCovix differs in that it is a portable, low cost, rapid point-of-care (POC) test with results in 10 minutes.
